Bart Cobert addresses the use of marijuana for medical purposes and the implications for Drug Safety.
What information should be examined in the study and work up of ADRs to determine whether the reaction is likely due to the drug or not.
Bart Cobert reviews the changes and updates happening with UK and EMA inspections.
We participate in safety reporting not only because it is required by law, but because we are HCPs whose first duty is always to protect the patient.
An update on the status of Brexit and the EMA move to Amsterdam.
Bart Cobert addresses confusing areas in Drug Safety and Pharmacovigilance including Brexit, basic terminology, date formatting and others.
Pharmacovigilance expert Bart Cobert examines the issues associated with language translation in PV and drug safety.
Bart Cobert examines the importance of, and differences between Data Monitoring Committees (DMCs) & Safety Assessment Committees (SACs).
Bart Cobert reviews the key requirements for the US-EU Privacy Shield, including implications for US Firms, Pharma Companies, and Drug Safety & Pharmacovigilance
